Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1 Study of IM-1617 in Participants With Advanced Malignancies
NCT07578571Phase 1Recruiting
- Sponsor
- Immunome
- Start
- May 2026
- Primary completion
- Jan 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of IM-1617 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 3 more (2 arms), sponsored by Immunome. Primary endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs) at 12 months, Incidence of AEs of interest (AEIs) at 12 months and 2 more. Started May 2026; status: recruiting.
02
Drugs
IM-1617
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)breast canceresophageal cancer
Beyond the preview
Go deeper on NCT07578571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07578571.